GW 842166

Drug Profile

GW 842166

Alternative Names: 842166; 842166X; GW 842166X; Non-cannabinoid CB2 receptor agonist - GlaxoSmithKline

Latest Information Update: 31 Aug 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-inflammatories; Non-opioid analgesics; Pyrans; Pyrimidines; Small molecules
  • Mechanism of Action Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dental pain; Musculoskeletal pain

Most Recent Events

  • 22 Apr 2005 Data presented at the at the 229th American Chemical Society National Meeting (229th-ACS-2005) have been added to the pharmacokinetics and Pain pharmacodynamics sections
  • 09 Dec 2004 Phase-I clinical trials in Pain in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top